Economic Burden of Follicular Non-Hodgkin’s Lymphoma

被引：0
作者：
Talia Foster
Jeffrey D. Miller
Mark E. Boye
Mason W. Russell
机构：
[1] Abt Bio-Pharma Solutions,Health Economic Research & Quality of Life Evaluation Services (HERQuLES)
[2] Inc.,undefined
[3] Eli Lilly and Company,undefined
[4] Abt Bio-Pharma Solutions,undefined
[5] Inc.,undefined
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
National Comprehensive Cancer Network; Fludarabine; National Comprehensive Cancer Network; Overall Response Rate; Watchful Waiting;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Follicular non-Hodgkin’s lymphoma (FNHL), a slow-growing cancer of the immune system, constitutes about 15–30% of all incident non-Hodgkin’s lymphoma in developed countries. Its incidence is rising worldwide. Patients can live many years, but FNHL is considered incurable. We systematically reviewed the English-language MEDLINE-indexed and non-indexed economic literature published in the past 10 years on FNHL, identifying 23 primary economic studies.
引用
收藏
页码：657 / 679
页数：22
相关论文
共 272 条
[1]  
Halpin D(2008)Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena COPD 5 187-200
[2]  
Hutchinson J(2006)Costs of chemotherapy for indolent follicular non-Hodgkin’s lymphoma in the UK: an observational study Acta Haematol 115 28-34
[3]  
Lloyd A(2006)Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma Onkologie 29 258-64
[4]  
Gray A(2005)Cost analysis of common treatment options for indolent follicular non-Hodgkin’s lymphoma Haematologica 90 1422-32
[5]  
Schmitz S(2002)Rituximab as third-line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin’s lymphoma: a systematic review and economic evaluation Health Technol Assess 6 1-85
[6]  
Aly F(2001)Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin’s lymphoma Leuk Lymphoma 40 565-79
[7]  
Steinmetz T(2005)Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin’s lymphoma cases during first-course chemotherapy Pharmacotherapy 25 668-75
[8]  
van Agthoven M(2000)The cost-effectiveness of treatment with rituximab compared to fludarabine for relapsed or refractory low-grade/follicular NHL. 2000 ASCO Annual Meeting Proceedings [abstract no. 1774] Proc Am Soc Clin Oncol 452 19-95
[9]  
Kramer MH(2007)Cost-effectiveness of rituximab maintenance therapy for patients with follicular lymphoma: the Spanish perspective [abstract 8092]. 2007 ASCO Annual Meeting Proceedings Part I [abstract no. 8092] J Clin Oncol 25 18-35
[10]  
Sonneveld P(2007)Cost-effectiveness of rituximab plus CVP for first-line treatment of advanced indolent lymphoma [abstract 6583]. 2007 ASCO Annual Meeting Proceedings Part I J Clin Oncol 25 18-54
12345678910